European stocks were subdued on Monday as investors awaited key economic data from the U.S., Europe and China this week for directional cues. <\/p>\n
Growth worries returned to the fore after data showed profits at China’s industrial companies rose at a much slower pace in October than the prior month.<\/p>\n
The pan European STOXX 600 was down 0.1 percent at 459.41 after gaining 0.3 percent on Friday. <\/p>\n
The German DAX slipped 0.1 percent, France’s CAC 40 was marginally lower and the U.K.’s FTSE 100 dipped 0.3 percent. <\/p>\n
Julius Baer fell over 1 percent on reports the Swiss wealth manager would review its private debt business<\/span>. <\/p>\n Veolia Environnement SA, a water, waste, and energy management solutions provider, rose about 1 percent in Paris after it agreed to sell its unit SADE-CGTH to NGE, an independent public works group, for 260 million euros.<\/p>\n Valneva jumped 2.2 percent. The drug maker said the European Medicines Agency has accepted its application for chikungunya vaccine candidate VLA1553.<\/p>\n Likewise, Sanofi rose over 1 percent after announcing positive results of Dupixent (dupilumab) Phase 3 trial in chronic obstructive pulmonary disease or COPD.<\/p>\n BP Plc dropped 0.8 percent and Shell fell 1.2 percent in London as Bent prices fell toward $80 a barrel following reports of disputes among OPEC+ members on their production quotas next year.<\/p>\n Rightmove jumped nearly 7 percent after the property portal raised part of its revenue guidance for 2023.<\/p>\n GSK edged up slightly after announcing positive headline results from phase III trial evaluating its elantamab mafodotin asset.<\/p>\n Insurer Aviva was marginally lower after it agreed to buy Optiom from Novacap and other minority shareholders for around \u00a3100m. <\/p>\n